Hepatitis C is a blood-borne viral liver infection historically associated with transfusions or needle exposure. Modern antiviral therapies can cure many cases. Underwriting evaluates treatment status, sustained virologic response, liver enzymes, fibrosis staging, and comorbidities.Successfully treated individuals with normal labs may qualify for improved rates; untreated or advanced disease increases risk.

With modern antivirals, many applicants achieve sustained virologic response. Advisors supply lab proof and specialist notes to pursue improved offers after cure.